LUIS FEBUS: Open Payments
NPI 1407026248 · EDGEWATER, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$995 in 57 payments from 8 companies in 2025. Trend: 2023 $752 · 2024 $1,166 · 2025 $995
Food & beverage: $995
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 15 | $311 |
| ABBVIE INC. | 16 | $266 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $175 |
| Teva Pharmaceuticals USA, Inc. | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $65 |
| Almatica Pharma LLC | 3 | $48 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
Products named: VRAYLAR, REXULTI, CAPLYTA, ABILIFY MAINTENA, UZEDY, TRINTELLIX, LOREEV XR, Qelbree.
Industry payments across NJ — which companies pay providers there.
